Mindray Q1 Results Confirm Turning Point Is Near, Maintaining Overweight

Overview

J.P. Morgan has released its commentary on Mindray’s Q1 2026 earnings, suggesting that the company’s most challenging period may have passed. Although reported net profit declined 11% year-on-year due to foreign-exchange losses, core operating performance remained solid after stripping out this factor. The report notes that overseas momentum is accelerating, domestic in vitro diagnostics (IVD) market share is rising faster than expected, and management remains constructive about China’s return to growth in 2026. Based on this, the firm anticipates that domestic revenue could resume positive growth in Q3 2026. However, given revisions to assumptions about overall growth in the domestic equipment market, the firm has lowered medium-to-long-term sales growth expectations by 1–2 percentage points and adjusted the target price slightly downward from RMB 235 to RMB 220, while maintaining an “overweight” rating, viewing Mindray as an intriguing turnaround story over the next one to two quarters.

Core views

Underlying results exceed reported figures; FX volatility masks core resilience. In Q1, Mindray’s sales grew 1% year-on-year, while net profit fell 11%. The report attributes the sharp decline primarily to significant swings in foreign-exchange losses. Excluding FX and tax impacts, Q1 net profit dropped just 4.9% year-on-year, indicating that the company’s core operating performance is far more robust than headline numbers suggest. Domestic business restructuring drives recovery, with IVD share gains leading the way. While China revenue still contracted 11.1% year-on-year, with monitoring and imaging products continuing to shrink, IVD market share trends offer a key leading indicator. The combined market share of immunology, biochemistry, and coagulation rose from 10% in mid-2025 to 12% by year-end 2025, reaching 13% in Q1 2026, putting the company on track to achieve its three-year goal of 20%. More than 80 MT8000 units were installed domestically in Q1, with over 50 going to large priority hospitals—these deployments serve as leading indicators for the coming 12–18 months, supporting expectations that domestic revenue will turn positive in Q3 2026 and re-accelerate in 2027. Meanwhile, emerging businesses such as minimally invasive surgery, interventional cardiology, and veterinary medicine collectively grew 18%, accounting for 23% of domestic revenue. Together, IVD and emerging businesses now comprise over 70% of total domestic sales, significantly reducing reliance on the still-soft equipment cycle. Overseas business accelerates, premiumization validated. International revenue now accounts for 53% of group sales and is on track to increase by 1–2 percentage points annually. In Q1, ultrasound system sales in international markets already surpassed full-year 2025 levels, validating the effectiveness of the company’s premiumization strategy. The company also highlighted specific product catalysts: a next-generation wearable patient-monitoring solution slated for launch in Europe in 2027, featuring continuous cuffless blood pressure measurement and AI-powered arrhythmia detection. Earnings forecasts and valuation adjustments. Based on management comments and the current environment, the firm deems its previous assumptions about overall growth in the domestic medical equipment market overly optimistic, lowering its medium-to-long-term sales growth trajectory for 2027–2031 from 11–15% to 10–14% (a reduction of 1–2 percentage points to the low double digits). Gross and net margin assumptions remain largely unchanged, resulting in a 2–9% downward revision to earnings forecasts for fiscal years 2027–2031. Accordingly, the target price has been reduced from RMB 235 to RMB 220.

Analysis framework

The firm employs a bottom-up fundamental analysis combined with DCF valuation. First, it disaggregates Q1 financial data, stripping out one-time or non-operational items (such as FX gains/losses) to reveal core operating trends and identify inflection points. Second, it tracks market-share changes in key segments (e.g., IVD) and installations of high-end products (e.g., MT8000, ultrasound systems) as leading indicators of future revenue growth. Third, it revises medium-to-long-term growth assumptions based on management guidance and reassessments of the macro environment (e.g., growth rates in the domestic medical equipment market). Finally, it uses a discounted cash-flow (DCF) model, setting a specific weighted average cost of capital (WACC) and terminal growth rate to derive the target price.

Methodology notes

• Valuation MethodologyDCF Discounted Cash Flow

  DCF Valuation Model

  The firm uses the DCF model to calculate the target price, assuming a market risk premium of 6.2%, a risk-free rate of 3.8% (based on China’s 10-year government bond yield), and a beta of 1.0, yielding a WACC of 10.0%. It further assumes a terminal growth rate of 3.0%, projecting future free cash flows and discounting them to estimate the company’s intrinsic value.

• Industry/Industrial Analysis FrameworkUpstream–Midstream–Downstream Value Chain Transmission

  Equipment Installations as Leading Indicators of Reagent Consumption

  The report notes that installations of devices like the MT8000 serve as leading indicators of rising reagent consumption over the next 12–18 months. This is a common analytical approach in the medical device industry, where upstream equipment deployment is used to anticipate sustained growth in downstream consumables revenue.

• Company Fundamentals and Financial Framework

  Core Profit Analysis After Removing Non-Recurring Items

  When analyzing Q1 results, the firm specifically excludes foreign-exchange losses and tax impacts to assess the true state of core operations. This approach helps eliminate short-term volatility and more accurately identify underlying business trends and turning points.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Mindray Bio-Medical Electronics (300760.SZ)

  Beneficiary, as China’s leading medical-device player, benefiting from rising IVD market share, overseas expansion, and growth in emerging businesses.

  Strengths

  Rapidly expanding IVD market share, high and accelerating share of international revenue, optimized emerging-business portfolio, successful premium-product validation.

  Weaknesses

  Domestic monitoring and imaging products remain under pressure, uncertainty surrounding DRG 3.0 implementation, and downward revisions to long-term growth expectations.

  Risks

  Price-pressure from centralized procurement, delays in new-product development, overseas operational risks, exchange-rate volatility, and procurement delays linked to anti-corruption efforts.

Key data

• Q1 2026 Sales Growth YoY1%Reported growth rate
• Q1 2026 Net Profit Growth YoY-11%Severely distorted by foreign-exchange losses
• Q1 2026 Core Net Profit Growth YoY-4.9%After excluding FX and tax impacts
• Domestic IVD Combined Market Share13%Q1 2026 figure, up 3 percentage points from mid-2025
• International Revenue Share53%On track to increase by 1–2 percentage points annually
• Emerging Businesses’ Share of Domestic Revenue23%Minimally invasive surgery, interventional cardiology, and veterinary medicine combined
• Target PriceRMB 220Lowered from RMB 235
• Medium-to-Long-Term Sales Growth Expectations10–14%For 2027–2031E, down 1–2 percentage points

Impact & implications

The report views Mindray as being at a turning point, with current softness viewed as cyclical rather than structural. The rapid rise in domestic IVD market share and strong growth in emerging businesses are reshaping the revenue mix and reducing dependence on traditional equipment cycles. Accelerating overseas expansion and successful premium product launches underscore the company’s global competitiveness. Despite lowering its long-term growth outlook and target price, the firm believes the current valuation does not yet fully reflect the impending recovery, making Mindray an attractive turnaround candidate over the next one to two quarters.

Risks

• Potential average selling price (ASP) pressure from China’s centralized procurement (VBP)
• Delays or failures in new-product development and commercialization
• Operational and market-expansion risks overseas
• Post‑merger integration risks
• Exchange-rate volatility
• Procurement delays caused by China’s anti-corruption campaign
• Reputational risks (product quality, safety, compliance, data security, etc.)

What to watch

• Whether domestic revenue returns to positive growth in Q3 2026
• Whether IVD market share continues advancing toward the 20% target
• The impact of DRG 3.0’s July rollout on China’s IVD market
• Whether the share of international revenue increases by 1–2 percentage points annually as targeted